The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

However, the overuse of antimicrobials has resulted in antimicrobial resistance (AMR) that has led to the emergence of ...

The findings show a complex intercontinental transport route for microbes like E. coli, Staphylococcus saprophyticus, and Clostridium difficile, protected from ultraviolet light and dehydration by ...

EXL-01 is under clinical development by Exeliom Biosciences and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

In the past, Clostridium difficile-associated disease (CDAD) was thought of mainly as a nosocomial disease associated with the use of broad-spectrum antibiotics, but its epidemiology seems to be ...